TY - JOUR
T1 - Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis
AU - Segal, Barbara
AU - Rhodus, Nelson L.
AU - Patel, Ketan
PY - 2008/12
Y1 - 2008/12
N2 - Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by inflammation involving large and small joints. Systemic manifestations as well as involvement of paraoral tissues contribute to morbidity. Tumor necrosis factor (TNF) plays a central role in RA by amplifying inflammation in multiple pathways that lead to joint destruction. Tumor necrosis factor inhibitors were first licensed for clinical use in 1998; 3 have been approved for the treatment of RA: Iinfliximab, etanercept, and adalimumab. The purpose of this paper is to review the pathogenesis of RA, the state of the art of therapy, and the most current information on the safety and efficacy of TNF inhibitors for treatment of RA.
AB - Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by inflammation involving large and small joints. Systemic manifestations as well as involvement of paraoral tissues contribute to morbidity. Tumor necrosis factor (TNF) plays a central role in RA by amplifying inflammation in multiple pathways that lead to joint destruction. Tumor necrosis factor inhibitors were first licensed for clinical use in 1998; 3 have been approved for the treatment of RA: Iinfliximab, etanercept, and adalimumab. The purpose of this paper is to review the pathogenesis of RA, the state of the art of therapy, and the most current information on the safety and efficacy of TNF inhibitors for treatment of RA.
UR - http://www.scopus.com/inward/record.url?scp=55549122297&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55549122297&partnerID=8YFLogxK
U2 - 10.1016/j.tripleo.2008.07.025
DO - 10.1016/j.tripleo.2008.07.025
M3 - Article
C2 - 18930662
AN - SCOPUS:55549122297
SN - 2212-4403
VL - 106
SP - 778
EP - 787
JO - Oral Surgery Oral Medicine and Oral Pathology
JF - Oral Surgery Oral Medicine and Oral Pathology
IS - 6
ER -